The DOI matches its Crossref record; 49 of the 50 references it cites were found in a registry or an index.
Promotion of Hepatocellular Carcinoma by the Intestinal Microbiota and TLR4
Open accessAbstract
Increased translocation of intestinal bacteria is a hallmark of chronic liver disease and contributes to hepatic inflammation and fibrosis. Here we tested the hypothesis that the intestinal microbiota and Toll-like receptors (TLRs) promote hepatocellular carcinoma (HCC), a long-term consequence of chronic liver injury, inflammation, and fibrosis. Hepatocarcinogenesis in chronically injured livers depended on the intestinal microbiota and TLR4 activation in non-bone-marrow-derived resident liver cells. TLR4 and the intestinal microbiota were not required for HCC initiation but for HCC promotion, mediating increased proliferation, expression of the hepatomitogen epiregulin, and prevention of apoptosis. Gut sterilization restricted to late stages of hepatocarcinogenesis reduced HCC, suggesting that the intestinal microbiota and TLR4 represent therapeutic targets for HCC prevention in advanced liver disease.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“Moreover, HSC mediators besides RSPO3, such as HGF, but possibly also neurotrophin-319 or epiregulin60 may be involved in additional aspects of HSC–hepatocyte cross-talk and—together with ECs29,59—collaboratively control hepatocyte health and functions.”
From Hepatic stellate cells control liver zonation, size and functions via R-spondin 3 (2025) · cites this paper as [60]
In the citing paper
“These pro-inflammatory mediators not only promote the development of CLD but also set the stage for the development of HCC13–15.”
From The gut microbiome and liver cancer: mechanisms and clinical translation (2017) · cites this paper as [13]
In the citing paper
“However, a failing gut barrier and alterations of the gut microbiota in chronic liver disease (CLD) contribute to chronic inflammation and the progression of liver diseases12, and thereby increase risk for the development of hepatocellular carcinoma (HCC) as the final stage of the disease process 13–15.”
From The gut microbiome and liver cancer: mechanisms and clinical translation (2017) · cites this paper as [13]
In the citing paper
“Nonetheless, the bacterial microbiota has an important role in promoting HCC in the setting of liver fibrosis, as demonstrated by reduced HCC formation in TLR4-deficient, germ-free and antibiotic-treated mice in a diethylnitrosamine (DEN) plus CCl4 model of HCC13.”
From The gut microbiome and liver cancer: mechanisms and clinical translation (2017) · cites this paper as [13]
In the citing paper
“It has become apparent that the endogenous commensal microbiota provides hepatoprotective signals and that complete absence of the gut microbiota results in increased liver injury — probably owing to an absence of TLR4-mediated activation of anti-apoptotic NF-κB signalling — and a subsequent increase in liver fibrosis, as demonstrated in several models13,75,76.”
From The gut microbiome and liver cancer: mechanisms and clinical translation (2017) · cites this paper as [13]
In the citing paper
“Consistent with previous studies71–73, treatment with nonabsorbable antibiotics resulted in a strong reduction of fibrosis despite increased liver injury13.”
From The gut microbiome and liver cancer: mechanisms and clinical translation (2017) · cites this paper as [13]
In the citing paper
“Experiments in bone-marrow-chimeric mice demonstrated that TLR4 expressed on liver-resident cells (which include hepatocytes, HSCs and Kupffer cells) is responsible for promotion of fibrogenesis and hepatocarcinogenesis13.”
From The gut microbiome and liver cancer: mechanisms and clinical translation (2017) · cites this paper as [13]
In the citing paper
“Accordingly, epiregulin-deficient mice displayed reduced hepatocarcinogenesis when treated with DEN+CCl413.”
From The gut microbiome and liver cancer: mechanisms and clinical translation (2017) · cites this paper as [13]
In the citing paper
“Conversely, inhibition of TLR4 signalling suppresses liver inflammation, fibrosis and HCC formation in mice and rats13,14,73.”
From The gut microbiome and liver cancer: mechanisms and clinical translation (2017) · cites this paper as [13]
In the citing paper
“Accordingly, chronic infusion of low-dose LPS via osmotic pumps promotes HCC development in mice13.”
From The gut microbiome and liver cancer: mechanisms and clinical translation (2017) · cites this paper as [13]
In the citing paper
“As such, HCC development induced by the combination of DEN and CCl4 was attenuated in gut-sterilized and germ-free mice compared with their specific pathogen-free counterparts13.”
From The gut microbiome and liver cancer: mechanisms and clinical translation (2017) · cites this paper as [13]
In the citing paper
“Accordingly, expression of the apoptosis marker cleaved caspase 3 in TLR4-deficient and gut-sterilized mice is inversely correlated with the formation of tumours13.”
From The gut microbiome and liver cancer: mechanisms and clinical translation (2017) · cites this paper as [13]
In the citing paper
“In HSCs, TLR4 activation leads to an NF-κB-mediated upregulation of the hepatomitogen epiregulin13.”
From The gut microbiome and liver cancer: mechanisms and clinical translation (2017) · cites this paper as [13]
In the citing paper
“Continuous gut sterilization by a cocktail of oral antibiotics, consisting of ampicillin, neomycin, metronidazole and vancomycin, effectively reduced the number and size of HCC induced by DEN+CCl4 or DMBA+HFD in mice13,15.”
From The gut microbiome and liver cancer: mechanisms and clinical translation (2017) · cites this paper as [13]
In the citing paper
“Of note, rifaximin reduces HCC development in the DEN–CCl4 model of HCC, albeit less efficiently than the quadruple antibiotics cocktail described above13.”
From The gut microbiome and liver cancer: mechanisms and clinical translation (2017) · cites this paper as [13]
In the citing paper
“Of note, administration of antibiotics at late stages of carcinogenesis, when microscopic tumours already existed, was more efficient at reducing HCC in mice than administration at earlier stages13.”
From The gut microbiome and liver cancer: mechanisms and clinical translation (2017) · cites this paper as [13]
In the citing paper
“supported by a large number of studies preclinical studies showing a drastic (≈80%) reduction of HCC development in murine models13–15.”
From The gut microbiome and liver cancer: mechanisms and clinical translation (2017) · cites this paper as [13]
In the citing paper
“Several studies have shown a key role for the TLR4 pathway as a mediator of the disease-promoting effects of the gut–liver axis in CLD and hepatocarcinogenesis13,14,73.”
From The gut microbiome and liver cancer: mechanisms and clinical translation (2017) · cites this paper as [13]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Immunity, Inflammation, and Cancer
Grivennikov, S. I., Greten, F. R., & Karin, M. (2010) · Cell · doi:10.1016/j.cell.2010.01.025 · Cited by 10,755
Inflammation and cancer: back to Virchow?
Balkwill, F., & Mantovani, A. (2001) · The Lancet · doi:10.1016/s0140-6736(00)04046-0 · Cited by 7,746
Recognition of Commensal Microflora by Toll-Like Receptors Is Required for Intestinal Homeostasis
Rakoff-Nahoum, S., Paglino, J., Eslami-Varzaneh, F., Edberg, S., & Medzhitov, R. (2004) · Cell · doi:10.1016/j.cell.2004.07.002 · Cited by 4,251
Matrix Crosslinking Forces Tumor Progression by Enhancing Integrin Signaling
Levental, K. R., Yu, H., Kass, L., Lakins, J. N., Egeblad, M., Erler, J. T., Fong, S. F. T., Csiszar, K., Giaccia, A., Weninger, W., et al. (2009) · Cell · doi:10.1016/j.cell.2009.10.027 · Cited by 4,101
Wang, C.-Y., Mayo, M., Korneluk, R., Goeddel, D., & Baldwin, A. (1998) · Science · doi:10.1126/science.281.5383.1680 · Cited by 2,950
Hepatocellular carcinoma in cirrhosis: Incidence and risk factors
Fattovich, G., Stroffolini, T., Zagni, I., & Donato, F. (2004) · Gastroenterology · doi:10.1053/j.gastro.2004.09.014 · Cited by 2,587
NF-κB functions as a tumour promoter in inflammation-associated cancer
Pikarsky, E., Porat, R. M., Stein, I., Abramovitch, R., Amit, S., Kasem, S., Gutkovich-Pyest, E., Urieli-Shoval, S., Galun, E., & Ben‐Neriah, Y. (2004) · Nature · doi:10.1038/nature02924 · Cited by 2,423
Schuppan, D., & Afdhal, N. H. (2008) · The Lancet · doi:10.1016/s0140-6736(08)60383-9 · Cited by 2,089
Metabolic Syndrome and Altered Gut Microbiota in Mice Lacking Toll-Like Receptor 5
Vijay-Kumar, M., Aitken, J. D., Carvalho, F. A., Cullender, T. C., Mwangi, S., Srinivasan, S., Sitaraman, S. V., Knight, R., Ley, R. E., & Gewirtz, A. T. (2010) · Science · doi:10.1126/science.1179721 · Cited by 2,068
Gender Disparity in Liver Cancer Due to Sex Differences in MyD88-Dependent IL-6 Production
Naugler, W. E., Sakurai, T., Kim, S., Maeda, S., Kim, K., Elsharkawy, A. M., & Karin, M. (2007) · Science · doi:10.1126/science.1140485 · Cited by 1,955
Flagged first, then by citations
1 of the 50 references couldn’t be matched to a known paper.
Research works printed but not linked: 1
- Toyoda, 1995, Epiregulin. A novel epidermal growth factor with mitogenic activity for rat primary hepatocytes, J. Biol. Chem., 270, 7495
Cited by
Sorted by citations
Llovet, J. M., Kelley, R. K., Villanueva, A., Singal, A. G., Pikarsky, E., Roayaie, S., Lencioni, R., Koike, K., Zucman-Rossi, J., & Finn, R. S. (2021) · Nature Reviews Disease Primers · doi:10.1038/s41572-020-00240-3 · Cited by 7,055
Interaction between microbiota and immunity in health and disease
Zheng, D., Liwinski, T., & Elinav, E. (2020) · Cell Research · doi:10.1038/s41422-020-0332-7 · Cited by 3,947
Inflammation and cancer: triggers, mechanisms, and consequences
Greten, F. R., & Grivennikov, S. I. (2019) · Immunity · doi:10.1016/j.immuni.2019.06.025 · Cited by 3,806
Obesity-induced gut microbial metabolite promotes liver cancer through senescence secretome
Yoshimoto, S., Loo, T. M., Atarashi, K., Kanda, H., Sato, S., Oyadomari, S., Iwakura, Y., Oshima, K., Morita, H., Hattori, M., et al. (2013) · Nature · doi:10.1038/nature12347 · Cited by 2,219
Inflammation-induced cancer: Crosstalk between tumours, immune cells and microorganisms
Elinav, E., Nowarski, R., Thaiss, C. A., Hu, B., Jin, C., & Flavell, R. A. (2013) · Nature reviews. Cancer · doi:10.1038/nrc3611 · Cited by 2,000
Immunotherapies for hepatocellular carcinoma
Llovet, J. M., Castet, F., Heikenwalder, M., Maini, M. K., Mazzaferro, V., Pinato, D. J., Pikarsky, E., Zhu, A. X., & Finn, R. S. (2022) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-021-00573-2 · Cited by 1,843
Dysbiosis and the immune system
Levy, M., Kolodziejczyk, A. A., Thaiss, C. A., & Elinav, E. (2017) · Nature Reviews Immunology · doi:10.1038/nri.2017.7 · Cited by 1,769
Schwabe, R. F., & Jobin, C. (2013) · Nature Reviews Cancer · doi:10.1038/nrc3610 · Cited by 1,689
Self-citationGut microbiome–mediated bile acid metabolism regulates liver cancer via NKT cells
Ma, C., Han, M., Heinrich, B., Fu, Q., Zhang, Q., Sandhu, M., Agdashian, D., Terabe, M., Berzofsky, J. A., Fako, V., et al. (2018) · Science · doi:10.1126/science.aan5931 · Cited by 1,508
Hepatic stellate cells as key target in liver fibrosis
Higashi, T., Friedman, S. L., & Hoshida, Y. (2017) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2017.05.007 · Cited by 1,485
The gut-liver axis and the intersection with the microbiome
Tripathi, A., Debelius, J., Brenner, D. A., Karin, M., Loomba, R., Schnabl, B., & Knight, R. (2018) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/s41575-018-0011-z · Cited by 1,480
Mederacke, I., Hsu, C. C., Troeger, J. S., Huebener, P., Mu, X., Dapito, D. H., Pradere, J.-P., & Schwabe, R. F. (2013) · Nature Communications · doi:10.1038/ncomms3823 · Cited by 1,443
Self-citationBile acids and the gut microbiota: metabolic interactions and impacts on disease
Collins, S. L., Stine, J. G., Bisanz, J. E., Okafor, C. D., & Patterson, A. D. (2023) · Nature Reviews Microbiology · doi:10.1038/s41579-022-00805-x · Cited by 1,214
Immunology in the liver — from homeostasis to disease
Heymann, F., & Tacke, F. (2016) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/nrgastro.2015.200 · Cited by 1,180
Liver fibrosis: Pathophysiology, pathogenetic targets and clinical issues
Parola, M., & Pinzani, M. (2018) · Molecular Aspects of Medicine · doi:10.1016/j.mam.2018.09.002 · Cited by 1,217
Pitt, J. M., Vétizou, M., Daillère, R., Roberti, M. P., Yamazaki, T., Routy, B., Lepage, P., Boneca, I. G., Chamaillard, M., Kroemer, G., et al. (2016) · Immunity · doi:10.1016/j.immuni.2016.06.001 · Cited by 1,060
Targeting hepatic macrophages to treat liver diseases
Tacke, F. (2017) · Journal of Hepatology · doi:10.1016/j.jhep.2017.02.026 · Cited by 1,003
Tumor-resident intracellular microbiota promotes metastatic colonization in breast cancer
Fu, A., Yao, B., Dong, T., Chen, Y., Yao, J., Liu, Y., Li, H., Bai, H., Liu, X., Zhang, Y., et al. (2022) · Cell · doi:10.1016/j.cell.2022.02.027 · Cited by 981
The Human Microbiota in Health and Disease
Wang, B., Yao, M., Lv, L., Ling, Z., & Li, L. (2017) · Engineering · doi:10.1016/j.eng.2017.01.008 · Cited by 916
Microenvironmental regulation of therapeutic response in cancer
Klemm, F., & Joyce, J. A. (2014) · Trends in Cell Biology · doi:10.1016/j.tcb.2014.11.006 · Cited by 789
Ren, Z., Li, A., Jiang, J., Zhou, L., Yu, Z., Lu, H., Xie, H., Chen, X., Shao, L., Zhang, R., et al. (2018) · Gut · doi:10.1136/gutjnl-2017-315084 · Cited by 782
Non-Cell-Autonomous Tumor Suppression by p53
Lujambio, A., Akkari, L., Simon, J., Grace, D., Tschaharganeh, D. F., Bolden, J. E., Zhao, Z., Thapar, V., Joyce, J. A., Krizhanovsky, V., et al. (2013) · Cell · doi:10.1016/j.cell.2013.03.020 · Cited by 766
Cell Death and Cell Death Responses in Liver Disease: Mechanisms and Clinical Relevance
Luedde, T., Kaplowitz, N., & Schwabe, R. F. (2014) · Gastroenterology · doi:10.1053/j.gastro.2014.07.018 · Cited by 785
Self-citationThe Role of Cancer-Associated Fibroblasts and Fibrosis in Liver Cancer
Affo, S., Yu, L.-X., & Schwabe, R. F. (2017) · Annual Review of Pathology: Mechanisms of Disease · doi:10.1146/annurev-pathol-052016-100322 · Cited by 757
Self-citationGut–Liver Axis in Alcoholic Liver Disease
Szabo, G. (2015) · Gastroenterology · doi:10.1053/j.gastro.2014.10.042 · Cited by 754
The clinical role of the TME in solid cancer
Giraldo, N. A., Sánchez-Salas, R., Peske, J. D., Vano, Y. A., Becht, É., Petitprez, F., Validire, P., Ingels, A., Cathelineau, X., Fridman, W. H., et al. (2018) · British Journal of Cancer · doi:10.1038/s41416-018-0327-z · Cited by 756
The gut–liver axis and gut microbiota in health and liver disease
Hsu, C. L., & Schnabl, B. (2023) · Nature Reviews Microbiology · doi:10.1038/s41579-023-00904-3 · Cited by 737
Role of the Microenvironment in the Pathogenesis and Treatment of Hepatocellular Carcinoma
Hernández–Gea, V., Toffanin, S., Friedman, S. L., & Llovet, J. M. (2013) · Gastroenterology · doi:10.1053/j.gastro.2013.01.002 · Cited by 726
Sterile inflammation in the liver
Kubes, P., & Mehal, W. Z. (2012) · Gastroenterology · doi:10.1053/j.gastro.2012.09.008 · Cited by 666
Risk factors and prevention of hepatocellular carcinoma in the era of precision medicine
Fujiwara, N., Friedman, S. L., Goossens, N., & Hoshida, Y. (2018) · Journal of Hepatology · doi:10.1016/j.jhep.2017.09.016 · Cited by 659
Ponziani, F. R., Bhoori, S., Castelli, C., Putignani, L., Rivoltini, L., CHIERICO, F. D., Sanguinetti, M., Morelli, D., Sterbini, F. P., Petito, V., et al. (2018) · Hepatology · doi:10.1002/hep.30036 · Cited by 684
Liu, Y., Gu, Y. H., Han, Y., Zhang, Q., Jiang, Z., Zhang, X., Huang, B., Xu, X., Zheng, J., & Cao, X. (2016) · Cancer Cell · doi:10.1016/j.ccell.2016.06.021 · Cited by 654
The gut microbiome and liver cancer: mechanisms and clinical translation
Yu, L.-X., & Schwabe, R. F. (2017) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/nrgastro.2017.72 · Cited by 634
Self-citationNonalcoholic Fatty Liver Disease: Pathogenesis and Disease Spectrum
Hardy, T., Oakley, F., Anstee, Q. M., & Day, C. P. (2016) · Annual Review of Pathology Mechanisms of Disease · doi:10.1146/annurev-pathol-012615-044224 · Cited by 641
Inflammation-induced IgA+ cells dismantle anti-liver cancer immunity
Shalapour, S., Lin, X.-J., Bastian, I. N., Brain, J., Burt, A. D., Aksenov, A. A., Vrbanac, A. F., Li, W., Perkins, A., Matsutani, T., et al. (2017) · Nature · doi:10.1038/nature24302 · Cited by 589
Ju, C., & Tacke, F. (2016) · Cellular & Molecular Immunology · doi:10.1038/cmi.2015.104 · Cited by 554
Global epidemiology of alcohol-associated cirrhosis and HCC: trends, projections and risk factors
Huang, D. Q., Mathurin, P., Cortez-Pinto, H., & Loomba, R. (2023) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/s41575-022-00688-6 · Cited by 553
Milosevic, I., Vujovic, A., Barac, A., Djelic, M., Korac, M., Radovanovic Spurnic, A., Gmizic, I., Stevanovic, O., Djordjevic, V., Lekic, N., et al. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20020395 · Cited by 551
Dysregulated Microbial Fermentation of Soluble Fiber Induces Cholestatic Liver Cancer
Singh, V., Yeoh, B. S., Chassaing, B., Xiao, X., Saha, P., Aguilera Olvera, R., Lapek, J. D., Zhang, L., Wang, W.-B., Hao, S., et al. (2018) · Cell · doi:10.1016/j.cell.2018.09.004 · Cited by 532
Deactivation of Hepatic Stellate Cells During Liver Fibrosis Resolution in Mice
Troeger, J. S., Mederacke, I., Gwak, G., Dapito, D. H., Mu, X., Hsu, C. C., Pradere, J., Friedman, R. A., & Schwabe, R. F. (2012) · Gastroenterology · doi:10.1053/j.gastro.2012.06.036 · Cited by 515
Self-citationExploring host–microbiota interactions in animal models and humansPreprint
Kostic, A. D., Howitt, M. R., & Garrett, W. S. (2013) · Genes & Development · doi:10.1101/gad.212522.112 · Cited by 516
Contribution of the Intestinal Microbiome and Gut Barrier to Hepatic Disorders
Chopyk, D. M., & Grakoui, A. (2020) · Gastroenterology · doi:10.1053/j.gastro.2020.04.077 · Cited by 504
Microbiome and Anticancer Immunosurveillance
Zitvogel, L., Ayyoub, M., Routy, B., & Kroemer, G. (2016) · Cell · doi:10.1016/j.cell.2016.03.001 · Cited by 478
Loo, T. M., Kamachi, F., Watanabe, Y., Yoshimoto, S., Kanda, H., Arai, Y., Nakajima-Takagi, Y., Iwama, A., Koga, T., Sugimoto, Y., et al. (2017) · Cancer Discovery · doi:10.1158/2159-8290.cd-16-0932 · Cited by 478
Mycotoxin: Its Impact on Gut Health and Microbiota
Liew, W.-P.-P., & Sabran, M. R. (2018) · Frontiers in Cellular and Infection Microbiology · doi:10.3389/fcimb.2018.00060 · Cited by 472
Human Gut Microbiota and Gastrointestinal Cancer
Meng, C., Bai, C., Brown, T. D., Hood, L., & Tian, Q. (2018) · Genomics Proteomics & Bioinformatics · doi:10.1016/j.gpb.2017.06.002 · Cited by 482
Gut microbiome, liver immunology, and liver diseases
Wang, R., Tang, R., Li, B., Ma, X., Schnabl, B., & Tilg, H. (2021) · Cellular & Molecular Immunology · doi:10.1038/s41423-020-00592-6 · Cited by 466
Cancer and the gut microbiota: An unexpected link
Zitvogel, L., Galluzzi, L., Viaud, S., Vétizou, M., Daillère, R., Merad, M., & Kroemer, G. (2015) · Science Translational Medicine · doi:10.1126/scitranslmed.3010473 · Cited by 465
Pierantonelli, I., & Svegliati‐Baroni, G. (2018) · Transplantation · doi:10.1097/tp.0000000000002480 · Cited by 473
Inflammation and Liver Cancer: Molecular Mechanisms and Therapeutic Targets
Yang, Y. M., Kim, S., & Seki, E. (2019) · Seminars in Liver Disease · doi:10.1055/s-0038-1676806 · Cited by 462
Gut–liver axis: barriers and functional circuits
Pabst, O., Hornef, M. W., Schaap, F. G., Cerovic, V., Clavel, T., & Bruns, T. (2023) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/s41575-023-00771-6 · Cited by 488
Zhu, Y., Yang, J., Xu, D., Gao, X.-M., Zhang, Z., Hsu, J. L., Li, C.-W., Lim, S.-O., Sheng, Y.-Y., Zhang, Y., et al. (2019) · Gut · doi:10.1136/gutjnl-2019-318419 · Cited by 419
Role of microbiota-derived short-chain fatty acids in cancer development and prevention
Mirzaei, R., Afaghi, A., Babakhani, S., Sohrabi, M., Hosseini‐Fard, S. R., Babolhavaeji, K., Akbari, S. K. A., Yousefimashouf, R., & Karampoor, S. (2021) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2021.111619 · Cited by 416
Chen, C., Kumar, D. B. U., Punj, V., Xu, J., Sher, L. S., Tahara, S. M., Hess, S. Y., & Machida, K. (2015) · Cell Metabolism · doi:10.1016/j.cmet.2015.12.004 · Cited by 392
RetractedGut microbiota-mediated inflammation in obesity: a link with gastrointestinal cancer
Cani, P. D., & Jordan, B. F. (2018) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/s41575-018-0025-6 · Cited by 383
Matson, V., Chervin, C. S., & Gajewski, T. F. (2021) · Gastroenterology · doi:10.1053/j.gastro.2020.11.041 · Cited by 385
Breast cancer in postmenopausal women is associated with an altered gut metagenome
Zhu, J., Liao, M., Yao, Z., Liang, W., Li, Q., Liu, J., Yang, H., Ji, Y., Wei, W., Tan, A., et al. (2018) · Microbiome · doi:10.1186/s40168-018-0515-3 · Cited by 377
Thomas, S., Izard, J., Walsh, E. K., Batich, K. A., Chongsathidkiet, P., Clarke, G. A., Sela, D. A., Muller, A. J., Mullin, J. M., Albert, K., et al. (2017) · Cancer Research · doi:10.1158/0008-5472.can-16-2929 · Cited by 398
Targeting Inflammation in Cancer Prevention and Therapy
Todoric, J., Antonucci, L., & Karin, M. (2016) · Cancer Prevention Research · doi:10.1158/1940-6207.capr-16-0209 · Cited by 375
Gut microbiome in HCC – Mechanisms, diagnosis and therapy
Schwabe, R. F., & Greten, T. F. (2020) · Journal of Hepatology · doi:10.1016/j.jhep.2019.08.016 · Cited by 375
Self-citationHepatocellular carcinoma: signaling pathways and therapeutic advances
Zheng, J., Wang, S., Xia, L., Sun, Z., Chan, K. M., Bernards, R., Qin, W., Chen, J., Xia, Q., & Jin, H. (2025) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-02075-w · Cited by 421
Role of the gut microbiota in anticancer therapy: from molecular mechanisms to clinical applications
Zhao, L.-Y., Mei, J.-X., Yu, G., Lei, L., Zhang, W.-H., Liu, K., Chen, X.-L., Kołat, D., Yang, K., & Hu, J.-K. (2023) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-023-01406-7 · Cited by 359
The HMGB1/RAGE axis triggers neutrophil-mediated injury amplification following necrosis
Huebener, P., Pradère, J., Hernandez, C., Gwak, G., Caviglia, J. M., Mu, X., Loike, J. D., Jenkins, R. E., Antoine, D. J., & Schwabe, R. F. (2014) · Journal of Clinical Investigation · doi:10.1172/jci76887 · Cited by 355
Self-citationBreast Cancer and Its Relationship with the Microbiota
Fernández, M. F., Reina-Pérez, I., Astorga, J. M., Rodríguez-Carrillo, A., Plaza-Díaz, J., & Fontana, L. (2018) · International Journal of Environmental Research and Public Health · doi:10.3390/ijerph15081747 · Cited by 350
Liedtke, C., Luedde, T., Sauerbruch, T., Scholten, D., Streetz, K. L., Tacke, F., Tolba, R. H., Trautwein, C., Trebicka, J., & Weiskirchen, R. (2013) · Fibrogenesis & Tissue Repair · doi:10.1186/1755-1536-6-19 · Cited by 346
The Yin and Yang of Toll-like receptors in cancer
Pradère, J., Dapito, D. H., & Schwabe, R. F. (2013) · Oncogene · doi:10.1038/onc.2013.302 · Cited by 344
Self-citationMicrobiota-liver axis in hepatic disease
Chassaing, B., Etienne‐Mesmin, L., & Gewirtz, A. T. (2013) · Hepatology · doi:10.1002/hep.26494 · Cited by 333
Diethylnitrosamine (DEN)-induced carcinogenic liver injury in mice
Tolba, R., Kraus, T., Liedtke, C., Schwarz, M., & Weiskirchen, R. (2015) · Laboratory Animals · doi:10.1177/0023677215570086 · Cited by 313
Tumor microenvironment-mediated immune evasion in hepatocellular carcinoma
Chen, C., Wang, Z., Ding, Y., & Qin, Y. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1133308 · Cited by 336
Influences of diet and the gut microbiome on epigenetic modulation in cancer and other diseases
Paul, B., Barnes, S., Demark-Wahnefried, W., Morrow, C., Salvador, C., Skibola, C., & Tollefsbol, T. O. (2015) · Clinical Epigenetics · doi:10.1186/s13148-015-0144-7 · Cited by 306
Ochi, A., Nguyen, A. H., Bedrosian, A. S., Mushlin, H. M., Zarbakhsh, S., Barilla, R., Zambirinis, C. P., Fallon, N. C., Rehman, A. U., Pylayeva‐Gupta, Y., et al. (2012) · The Journal of Experimental Medicine · doi:10.1084/jem.20111706 · Cited by 309
The Human Microbiome and Cancer
Rajagopala, S. V., Vashee, S., Oldfield, L. M., Suzuki, Y., Venter, J. C., Telenti, A., & Nelson, K. E. (2017) · Cancer Prevention Research · doi:10.1158/1940-6207.capr-16-0249 · Cited by 325
Toll‐like receptors in alcoholic liver disease, non‐alcoholic steatohepatitis and carcinogenesis
Roh, Y. S., & Seki, E. (2013) · Journal of Gastroenterology and Hepatology · doi:10.1111/jgh.12019 · Cited by 309
Recent advancement of molecular mechanisms of liver fibrosis
Seki, E., & Brenner, D. A. (2015) · Journal of Hepato-Biliary-Pancreatic Sciences · doi:10.1002/jhbp.245 · Cited by 302
The HMGB1/RAGE axis triggers neutrophil-mediated injury amplification following necrosis
Huebener, P., Pradère, J., Hernandez, C., Gwak, G., Caviglia, J. M., Mu, X., Loike, J. D., Jenkins, R. E., Antoine, D. J., & Schwabe, R. F. (2019) · Journal of Clinical Investigation · doi:10.1172/jci126975 · Cited by 301
Self-citationRole of nonresolving inflammation in hepatocellular carcinoma development and progression
Yu, L., Yan, L., & Wang, H. (2018) · npj Precision Oncology · doi:10.1038/s41698-018-0048-z · Cited by 309
Recent progress in treatment of hepatocellular carcinoma.
Chen, Z., Xie, H., Hu, M., Huang, T., Hu, Y., Sang, N., & Zhao, Y. (2020) · PubMed Central · Cited by 299
Targeted and Immune-Based Therapies for Hepatocellular Carcinoma
Greten, T. F., Lai, C. W., Li, G., & Staveley-O’Carroll, K. F. (2018) · Gastroenterology · doi:10.1053/j.gastro.2018.09.051 · Cited by 295
Scott, A. J., Alexander, J. L., Merrifield, C. A., Cunningham, D., Jobin, C., Brown, R., Alverdy, J., O’Keefe, S. J., Gaskins, H. R., Teare, J., et al. (2019) · Gut · doi:10.1136/gutjnl-2019-318556 · Cited by 288
Probiotics in Medicine: A Long Debate
Stavropoulou, E., & Bezirtzoglou, E. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.02192 · Cited by 312
Zhang, H.-L., Yu, L.-X., Yang, W., Tang, L., Lin, Y., Wu, H., Zhai, B., Tan, Y.-X., Shan, L., Liu, Q., et al. (2012) · Journal of Hepatology · doi:10.1016/j.jhep.2012.06.011 · Cited by 281
The influence of gut microbiota on drug metabolism and toxicity
Li, H., Jiaojiao, H., & Jia, W. P. (2015) · Expert Opinion on Drug Metabolism & Toxicology · doi:10.1517/17425255.2016.1121234 · Cited by 279
Recent clinical trends in Toll‐like receptor targeting therapeutics
Anwar, M. A., Shah, M., Kim, J., & Choi, S. (2018) · Medicinal Research Reviews · doi:10.1002/med.21553 · Cited by 281
The gut microbiota: A treasure for human health
Li, D., Wang, P., Wang, P., Hu, X., & Chen, F. (2016) · Biotechnology Advances · doi:10.1016/j.biotechadv.2016.08.003 · Cited by 271
Gut Microbiome Directs Hepatocytes to Recruit MDSCs and Promote Cholangiocarcinoma
Zhang, Q., Ma, C., Duan, Y., Heinrich, B., Rosato, U., Diggs, L. P., Ma, L., Roy, S., Fu, Q., Brown, Z. J., et al. (2020) · Cancer Discovery · doi:10.1158/2159-8290.cd-20-0304 · Cited by 266
TREM-1 and its potential ligands in non-infectious diseases: from biology to clinical perspectives
Tammaro, A., Derive, M., Gibot, S., Leemans, J. C., Florquin, S., & Dessing, M. C. (2017) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2017.02.043 · Cited by 253
Zhang, Z., Tang, H., Chen, P., Xie, H., & Tao, Y. (2019) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-019-0074-5 · Cited by 263
Lipidomic biomarkers and mechanisms of lipotoxicity in non-alcoholic fatty liver disease
Svegliati‐Baroni, G., Pierantonelli, I., Torquato, P., Marinelli, R., Ferreri, C., Chatgilialoglu, C., Bartolini, D., & Galli, F. (2019) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2019.05.029 · Cited by 255
Pathogenesis and treatment of non-alcoholic steatohepatitis and its fibrosis
Lee, K., Wu, P.-S., & Lin, H. (2022) · Clinical and Molecular Hepatology · doi:10.3350/cmh.2022.0237 · Cited by 269
Elkrief, A., Derosa, L., Kroemer, G., Zitvogel, L., & Routy, B. (2019) · Annals of Oncology · doi:10.1093/annonc/mdz206 · Cited by 246
The story of HCC in NAFLD : from epidemiology, across pathogenesis, to prevention and treatment
Margini, C., & Dufour, J. (2015) · Liver International · doi:10.1111/liv.13031 · Cited by 252
Nanotechnology intervention of the microbiome for cancer therapy
Song, W., Anselmo, A. C., & Huang, L. (2019) · Nature Nanotechnology · doi:10.1038/s41565-019-0589-5 · Cited by 248
Mouse models of hepatocellular carcinoma: an overview and highlights for immunotherapy research
Brown, Z. J., Heinrich, B., & Greten, T. F. (2018) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/s41575-018-0033-6 · Cited by 253
Emerging immunotherapy for HCC: A guide for hepatologists
Foerster, F., Gairing, S. J., Ilyas, S. I., & Galle, P. R. (2022) · Hepatology · doi:10.1002/hep.32447 · Cited by 245
The Role of EREG/EGFR Pathway in Tumor Progression
Cheng, W., Feng, P., Lee, K., Chen, K.-Y., Sun, W.-L., Hiệp, N. V., Luo, C.-S., & Wu, S. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms222312828 · Cited by 246
Emerging roles of the microbiome in cancer
Bultman, S. J. (2014) · Carcinogenesis · doi:10.1093/carcin/bgt392 · Cited by 239
Oral–Gut Microbiome Axis in Gastrointestinal Disease and Cancer
Park, S.-Y., Hwang, B.-O., Lim, M., Ok, S.-H., Lee, S., Chun, K., Park, K.-K., Hu, Y., Chung, W., & Song, N. (2021) · Cancers · doi:10.3390/cancers13092124 · Cited by 247
Hu, J., Wang, C., Huang, X., Yi, S., Su, P., Zhang, Y., Yuan, G., Cao, Q., Ye, X., & Li, H. (2021) · Cell Reports · doi:10.1016/j.celrep.2021.109726 · Cited by 236
The Spectrum of Achalasia: Lessons From Studies of Pathophysiology and High-Resolution Manometry
Kahrilas, P. J., & Boeckxstaens, G. E. (2013) · Gastroenterology · doi:10.1053/j.gastro.2013.08.038 · Cited by 236
NAFLD‐related hepatocellular carcinoma: The growing challenge
Shah, P. A., Patil, R., & Harrison, S. A. (2022) · Hepatology · doi:10.1002/hep.32542 · Cited by 270
Metadata
- Authors
- Dapito, D. H., Mencin, A., Gwak, G.-Y., Pradere, J.-P., Jang, M.-K., Mederacke, I., Caviglia, J. M., Khiabanian, H., Adeyemi, A., Bataller, R., Lefkowitch, J. H., Bower, M., Friedman, R., Sartor, R. B., Rabadan, R., & Schwabe, R. F.
- Affiliations
- Columbia University (US)
- Samsung Medical Center (KR)
- Hospital Clínic de Barcelona (ES)
- University of North Carolina at Chapel Hill (US)
- Corresponding author
- Schwabe, Robert F.
- ORCID
- Venue
- Cancer Cell
- Publisher
- Elsevier BV
- Published
- 2012-04
- Volume
- 21
- Issue
- 4
- Pages
- 504-516
- ISSN
- 1535-6108 (ISSN-L)
- PMC
- PMC3332000
- OpenAlex
- W2085153086
- Cited by
- 1,346
- References
- 50
- Citations by year
- 2026: 63 · 2025: 103 · 2024: 106 · 2023: 111 · 2022: 149 · 2021: 133 · 2020: 129 · 2019: 104 · 2018: 93 · 2017: 94 · 2016: 79 · 2015: 64 · 2014: 48 · 2013: 51 · 2012: 16
- FWCI
- 36.26
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Licence
- www.elsevier.com/tdm/userlicense/1.0/ (tdm)
- www.elsevier.com/legal/tdmrep-license (tdm)
- www.elsevier.com/open-access/userlicense/1.0/ (vor, 472 d)
- doi.org/10.15223/policy-017 (stm-asf)
- doi.org/10.15223/policy-037 (stm-asf)
- doi.org/10.15223/policy-012 (stm-asf)
- doi.org/10.15223/policy-029 (stm-asf)
- doi.org/10.15223/policy-004 (stm-asf)
- Locations
- Cancer Cell (publishedVersion)
- PubMed (publishedVersion)
- Europe PMC (PubMed Central) (acceptedVersion)
- PubMed Central (acceptedVersion)
- Carolina Digital Repository (University of North Carolina at Chapel Hill) (submittedVersion, cc-by)
- UNC Libraries
- Funders
- National Institutes of Health (1F31 DK091980-01, P40RR018603, R01AA020211, R01DK076920, U54CA163111)
- Topics
- Health Sciences › Medicine › Hepatology › Hepatocellular Carcinoma Treatment and Prognosis
- Health Sciences › Medicine › Hepatology › Liver physiology and pathology
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Gut microbiota and health
- Keywords
- hepatocellular carcinoma, gut microbiota, TLR4, gut-liver axis, chronic liver injury, hepatocarcinogenesis, bacterial translocation, epiregulin, apoptosis, HCC prevention, liver fibrosis, liver inflammation
- MeSH terms
- Animals, Epidermal Growth Factor, Humans, Intestines, Liver Diseases, Liver Neoplasms, Experimental, Mice, Inbred C57BL, Tumor Cells, Cultured, Apoptosis, Bacterial Translocation, Cell Proliferation, Toll-Like Receptor 4, Mice, Epiregulin
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
